Navigation Links
Marshall Edwards Adds $2 Million in Private Placement
Date:12/29/2011

ical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and expects final data from the trial in the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344. The Company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rig
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... STAMFORD, Conn. , Aug. 31, 2015 /PRNewswire/ ... Ltd., and Purdue Pharma L.P. announced today that they ... development and commercialization of Eisai,s clinical candidate lemborexant (development ... III clinical development for the treatment of insomnia. ... and Purdue Pharma will share the costs of lemborexant ...
(Date:8/31/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical ... therapeutics for the treatment of diseases of the central ... BNC101 IND submission has passed review by the US ... a Phase 1 clinical trial in patients with metastatic ... prior to 31 December 2015. Bionomics, CEO ...
(Date:8/31/2015)... , Aug. 31, 2015 Research ... addition of the "Prescription Pain Drugs - ... Marijuana - Global Markets, Competitors and Opportunities: 2015 ... their offering. Pain is defined ... with actual or potential tissue damage. At some ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... DIEGO, Jan. 7, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... has entered into definitive agreements to sell 8,184,556 units ... certain healthcare-focused investors, and other institutional investors for a ... to ADVENTRX of approximately $22.5 million.  Each unit consists ...
... Jan. 7, 2011 WaferGen Biosystems, Inc. (OTC Bulletin ... state-of-the-art genomic analysis systems, today announced that it will ... Annual OneMedForum Business Development and Investment Conference for emerging ... JP Morgan Healthcare Conference in San Francisco, January 11-13, ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million 2ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million 3WaferGen to Present at OneMedForum San Francisco 2011 2
(Date:9/1/2015)... , ... September 01, 2015 , ... Dr. Trace Curry ... JourneyLite of Cincinnati. In the last month the FDA has approved two intra-gastric ... ™. These procedures represent the first incisionless, reversible, weight loss procedures available to ...
(Date:9/1/2015)... Sarasota, Fla. (PRWEB) , ... September 01, 2015 , ... ... to be one of the first in the area to offer RADIESSE® filler treatment ... help to reduce the prominence of tendons and veins in the hands, delivering smooth, ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, ... safety labels and stickers to keep little ones' safety top of mind at all ... has a particular focus. According to the JPMA's Baby Safety Zone website, this year's ...
(Date:8/31/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 , ... ... function and other clinically relevant measures for physical therapy patients. The Registry is being ... President of FOTO, Inc. stated "We are happy to be selected to contribute FOTO ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... updated to include a wealth of information for specific translation services within the ... expertise and an incredible track record of successful work. , ITC Global Translations ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3
... and Learn for a Lifetime", MILPITAS, Calif., April ... maker of OneTouch(R) Blood Glucose Meters for,people with diabetes, ... for kids with diabetes to attend a diabetes camp ... which runs through,May 20, is available at http://www.DiabetesAndKids.com ...
... China, April 11 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) ... and distributor of healthcare related disinfectants in ... Shanghai LiKang,Disinfection Hi-Tech Company, Ltd., (LiKang Disinfectant) ... (MOH) and Ministry of Human Resources and,Social ...
... says Chicago father of 3 who has early-onset version ... foreman Jim Mueller was in his early 30s when his ... equipment, where he was, and where he was going. Sometimes ... nothing prepared the Mueller family for the doctor,s verdict. , ...
... to evaluate palpable breast lesions, they can rule out ... conducted by researchers at Baystate Health in Springfield, MA. ... protocol. , We were interested in finding out ... together, in excluding breast cancer in women with palpable ...
... ablation in the treatment of colorectal liver metastases is ... to a recent study conducted by researchers at Charit, ... ablation (RFA) has become a widely used treatment option ... from some primary tumors, if surgery is not an ...
... April 11 Registration is now,open for ... for,environmentally preferable practices and green building. The ... Care Without Harm,along with partners Consorta, the ... Pittsburgh Medical Center., CleanMed attracts major ...
Cached Medicine News:Health News:OneTouch(R) Laugh & Learn Sweepstakes to Award Scholarships for Summer Camp Experiences to Children with Diabetes 2Health News:OneTouch(R) Laugh & Learn Sweepstakes to Award Scholarships for Summer Camp Experiences to Children with Diabetes 3Health News:Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics 2Health News:Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics 3Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 2Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 3Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 4Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 5Health News:Mammography plus sonography can help rule out breast cancer in patients with palpable lesions 2Health News:Creating Healing Environments: Healthcare Industry's Largest Sustainability Conference to be Held May 20-22 in Pittsburgh 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: